Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Johnson & Johnson makes a significant investment in Sail Biomedicines, committing $785 million up front, including a $465 million equity investment, to advance its lead CAR-T program.

PRIVATEJul 30, 2026•10 days ago

Amount Raised

$465 Million

Round Type

Venture - Series Unknown

SomervilleBiotechnologyHealth CareArtificial Intelligence

Investors

Johnson & Johnson

Description

Johnson & Johnson announced a deal to work with biotechnology firm Sail Biomedicines, including an initial equity investment of $465 million. The funding aims to help advance Sail's CAR-T therapy program, which is still in preclinical testing. J&J has also secured an exclusive option to acquire Sail for $2.58 billion in the future. This represents a strategic move into in vivo cell therapy by one of the industry giants.

Company Information

Company

Sail Biomedicines

Location

Somerville, Pennsylvania, United States

About

Sail Biomedicines, a Flagship Pioneering company, is generating tomorrow’s medicines today through the language of life. Sail’s platform combines first-in-category translatable circular RNA technology (Endless RNA™ or eRNA), and proprietary programmable nanoparticles, utilizing natural components, to comprehensively program medicines for the first time. By leveraging its rapid prototyping and testing bioplatform, Sail is building a wealth of data, enabling unparalleled use of state-of-the-art AI techniques for the integrative design of RNA medicines with unprecedented performance and broad applicability. For more, visit www.sail.bio and follow us on X (formerly Twitter) @SailBiomeds and on LinkedIn.

Related People

Suggested for you
2 contacts
Verified contactsScott, Director, Operations and Facilities hidden
Predictive Intelligence
Strategic

ML-powered predictions for Sail Biomedicines's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.